Skip to main content
HHS Author Manuscripts logoLink to HHS Author Manuscripts
. Author manuscript; available in PMC: 2017 May 25.
Published in final edited form as: Parasitol Today. 1994 Nov;10(11):419–423. doi: 10.1016/0169-4758(94)90171-6

Economic Losses Caused by Foodborne Parasitic Diseases

Tanya Roberts 1, K Darwin Murrell 2, Suzanne Marks 3
PMCID: PMC5444537  NIHMSID: NIHMS859252  PMID: 15275523

Abstract

Fragmentary data indicate that zoonotic parasites cause human illnesses with medical costs and productivity and disability losses totalling billions of dollars annually. Food is an important vehicle for some of these parasitic diseases. The cost to public health is not reflected in the priorities given to these parasitic diseases in either research or public health planning. In this article, Tanya Roberts, Darwin Murrell and Suzanne Marks discuss the cost of toxoplasmosis, taeniasis, cysticercosis, trichinellosis and other foodborne parasitic diseases.


Worldwide economic losses caused by foodborne parasitic zoonoses are difficult to assess. The prevalence of specific parasites in the food supply varies between countries and regions, and data on prevalence are fragmentary. Dietary preferences and food preparation practices affect the probability of eating contaminated food. For example, consuming raw or undercooked meat, poultry or seafood increases risk. There are few studies estimating the costs of parasitic foodborne disease. Generally, these studies estimate medical costs and productivity losses due to worker illness or death, but may include different cost categories or use different methodologies and assumptions. This review summarizes the available human illness cost estimates of the following foodborne parasitic zoonoses: toxoplasmosis, taeniasis/cysticercosis, trichinellosis and opisthorchiasis. The cost estimates are fragmentary and are primarily for developed countries because of the lack of suitable economic data from other countries.

Costs of congenital toxoplasmosis

USA

In the USA, the human illness losses due to congenital toxoplasmosis have been estimated at US$0.4–8.8 billion annually (the wide range reflects uncertainty about the number of infected babies)1,2. In this report, we are taking a middle estimate of one case per 1000 live births, or 4179 US cases annually. Costs are calculated using Roberts and Frenkel’s methodology1 and updated to 1992 prices. Three types of cost are estimated: (1) medical costs, (2) income losses, and (3) costs incurred by special education or residential care required as a result of a handicap caused by congenital toxoplasmosis.

Medical costs are incurred by those ill as infants and those with consequent visual impairment. For the 2% of cases who die, three weeks of intensive care hospitalization were assumed, at a cost of US$55442 per case. For the 11% of cases who survive severe illness, two weeks in intensive care and two weeks in a regular hospital room were assumed, plus fees for physician services and pharmaceuticals, resulting in a total cost of US$53072 per case. Diagnostic tests for sequelae were estimated at US$3183 for each surviving child. The total medical costs are estimated at US$45 million (Table 1).

Table 1.

Congenital toxoplasmosis US medical costs 1992

Clinical illness or procedure % of cases Loss per casea (US$) Cases (No.) Total loss (US$ million)
Severe neonatal illness
 Deaths 2 55442 84 4.6
 Survivors 11 53072 460 24.4
Diagnostic tests (average) 100 3183 4179 13.3
 Yearly eye exam 48 1257 2006 2.5
 Strabismusb 8 483 341 0.2
45.0
a

Rounded to nearest US$ 100.

b

Deviation of the eye (includes cost to correct).

Consequences of fetal/newborn infection with Toxoplasma gondii were estimated to result in severe mental retardation in 33% of cases, moderate visual impairment (53%), cross-eyed vision (20%), slight mental retardation (23%), moderate hearing loss in one ear (10%) and moderate mental retardation (17%).

Income losses due to impairment include working in a lower-skilled job for lower pay (than would an unimpaired individual), unemployment or death. The largest component of income loss was the reduced earning of persons born severely or moderately retarded because of fetal acquisition of toxoplasmosis. Conley (cited in Ref. 1) found that slightly retarded adults (IQs between 50 and 70) were able to find US jobs at wages close to the average income of the general population, moderately retarded persons (IQs between 40 and 49) frequently found jobs at wages only 19% of the average, and few retardates with IQs below 40 were employed. Combining the income loss due to lower wages and the loss due to greater unemployment, the total income loss was estimated at 27% for the slightly retarded, 93% for the moderately retarded and 100% for severely retarded men and women. The income loss of persons with a severe visual impairment is estimated at 70% and the hearing impaired have a 56% income loss. Most of the total annual income loss of US$2.8 billion (assuming a steady state of disease) is due to severe and moderate mental retardation (Table 2).

Table 2.

Congenital toxoplasmosis US annual productivity lossesa

Disability or death Income loss (%) Loss per case (US$) Total loss (US$ million)
Fetal/perinatal deaths 40b 433922 36.3
Severely retarded 100 1084804 1496.0
Moderately retarded 93 1008868 716.7
Slightly retarded 27 292897 281.5
Blind 70 759363 253.9
Deaf 56 607490 50.8
2835.2
a

1992 US$ values.

b

This is an understatement of income loss. The income loss for fetal deaths is assumed to be 40% because these are not likely to be replaced by another infant32.

The costs of special education have also been estimated. Half of the severely retarded were assumed to be living in institutions and the other half to be living at home until the age of 18 years. The severely retarded dominated the estimates, largely because of the high costs of residential care. Special education costs are estimated at US$2.4 billion (Table 3).

Table 3.

Congenital toxoplasmosis US special education and residential care costs 1992

Disability Cases affected (%) Loss per case a (US$) Cases (No.) Total loss (US$ million)
Severely retarded
 Lifetime residential care (40 years) 16.5 2049231 690 1413
 Live-in at home for 18 yearsb 16.5 160276 690 111
16028c 11
Residential care after age 18 829919 572
Moderately retarded 17.0 125690 710 89
Slightly retarded 23.0 69828 961 67
Blind 8.0 334
 Special education for 15 years 261048 87
 Additional expense 26105 9
Deaf 2.0 84
 Special education for 15 years 184238 15
 Additonal expense 187424 2
2376
a

Costs are discounted by a 3% annual interest rate to arrive at a present value assuming a 40-year life span.

b

The cost of schooling for the first 18 years at home.

c

10% of the cost of schooling for the family’s additional expenses.

Of the three types of preventable cost estimated, the income loss is two-thirds that of the total cost. The largest contributors to the income loss are infected persons who are severely or moderately retarded. Next in importance are special education and residential care costs. Medical costs comprise a very small part of the estimated preventable losses.

UK

Congenital human toxoplasmosis illness costs for clinical cases (excluding subclinical cases) in the UK have been estimated at US$1.2–12 million (updated to 1992) (Ref. 3). The greatest loss was due to income loss and residential care for the moderately mentally retarded. Income loss is more narrowly defined than in the US study. Also, a lower percentage of mental retardation and other sequelae were estimated in the UK. Based on the estimates of the effects of mental retardation on income from the UK and the US studies, the severely retarded will not be employable and have a 100% income loss. For the moderately retarded group, a 67% income loss is assumed in the UK and greater than 90% income loss in the USA. For the slightly retarded, women’s reduced income is comparable for both studies, but the US men have only an 18% income loss compared with 33% in the UK.

The estimation method of Henderson and colleagues3 is similar to that of Roberts and Frenkel1, although the productivity/income loss is more narrowly defined and a higher discount rate (5% rather than 3%) is used3. Neither study estimated psychological costs caused by family disruption and the stress of having a mentally retarded child, nor did they place a value on the fact that the mentally retarded have fewer friends and are less likely to marry than are persons with an average IQ.

Worldwide

In Europe, the rate of congenital toxoplasmosis may be greater than in the US. Lamb and mutton may be a greater source of dietary risk due to a greater preference for undercooked or raw meat, especially in France4. The estimated occurrence of congenital toxoplasmosis in live births and the total number of cases in the US, the UK, Australia and a selection of European countries are given in Table 4.

Table 4.

Congenital toxoplasmosis incidence in selected countries

Country Estimated % of live births Live births (millions) (1992) Estimated cases (No.) Ref.
USA 0.01–0.026 4.2 420–10920 1
Europe 0.03–0.6 6.1 18396–36792 5
UK 0.03–0.3 0.8 243–2428 3
France 0.2–0.3 0.7 1479–2219 4
Switzerland 0.1 0.1 90 4
Belgium 0.2 0.1 260 4
Former Czechoslovakia 0.2 0.2 440 4
Australia 0.2 0.3 534 4
Worldwide 0.1–0.8 140.9 140900–1127200 6

Toxoplasmosis in AIDS patients

Toxoplasmic encephalitis, marked by dementia and seizures, is the most commonly recognized cause of central nervous system opportunistic infection in AIDS patients7. Between 15% and 68% of all adults in the USA have antibodies to T. gondii, and 30% of AIDS patients seropositive for T. gondii will develop toxoplasmic encephalitis8,9. Multiplying these percentages times by approximately 50000 (new US AIDS cases in 1992), there were an estimated 2250–10200 new cases of toxoplasmic encephalitis in 1992. Hay et al.10 calculated the cost of a treatment protocol for toxoplasmic encephalitis to be US$10379 per case (1992), and the total cost for treatment was US$23–106 million (1992 dollars) using Hay’s analysis811. These costs are probably an underestimate of the real costs of toxoplasmosis in immunocompromised patients because of the well-documented difficulties in diagnosis12.

Corroborating this estimate are 1360 annual hospitalizations for toxoplasmic encephalitis recorded in the US National Hospital Discharge Survey between 1987 and 1990 (Ref. 13). Toxoplasmosis hospitalizations for infections at locations other than the central nervous system averaged an additional 3630 cases annually, and were concentrated in the 25–44 age group13.

This problem is obviously not confined to the US. In Germany, between 40 and 70% of the population is estimated to have antibodies to T. gondii; in France, 80%; in Indonesia, 1–60%; in Hong Kong, 9.8%; and in Africa, 15–60%14. These high levels of antibodies indicate significant risk of toxoplasmic encephalitis to AIDS patients.

Taeniasis/cysticercosis

Taeniasis, a tapeworm infection of the human intestinal tract, results from the ingestion of the cysticercus (larval stage) in raw or undercooked infected pork (Taenia solium infection) or beef (T. saginata). In the USA, diagnostic laboratories have diagnosed Taenia tapeworms in 0.056% of stool specimens, over half of which were reported from western states7. Many cases of taeniasis are asymptomatic (T. solium and T. saginata). An annual average of 1104 tapeworm cases were documented by the Centers for Disease Control and Prevention (CDC) between 1978 and 1981 (Ref. 7). Medical treatment to eliminate the tapeworm generally requires two visits to a physician, at least one lab test and drug therapy (T. Roberts and K.D. Murrell, abstract*). The medical costs plus the wage losses for these mild cases are estimated at US$238 per case; annual costs for 1104 cases in the USA total US$263228.

Forty-five million people have been estimated to harbor T. saginata: 11 million in Europe, 15 million in Asia, 18 million in Africa, and one million in South America (J.T.R. Robinson, MSc Thesis, University of Pretoria, South Africa). Estimates are especially high in the former Yugoslavia15. In Laos, 12% are infected with either T. saginata or T. solium15. Taenia solium remains a major public health problem in Latin America: infection rates range from 0.3% in Chile to 1.13% in Guatemala16.

Cysticercosis

Cysticercosis, which typically affects the brain or other parts of the central nervous system, can result when humans infected with T. solium (acquired from consuming inadequately cooked infected pork) handle food and contaminate it with tapeworm eggs. Cysticercosis is an indirect foodborne disease, but it is discussed here because of the seriousness of the disease and the extent of human infection in Latin America and among US immigrants.

In Los Angeles, Sorvillo found the brain to be the cyst infection site in 86% of cases (the eye was the infection site in 7%). Six percent of the cases were fatal16. Neurocysticercosis (cysticercosis of the central nervous system) may lead to other serious illness, as shown in a recent study in Mexico, which documented neurocysticercosis as the most common cause of late onset epilepsy17. The number of neurocysticercosis cases in the USA have been increasing. An annual average of 1133 cysticercosis cases were diagnosed at US hospitals between 1987 and 1990 (Ref. 13). Part of the recent increase in cases is due to improved diagnostic capabilities by either computer tomography (CT) or magnetic resonance imaging (MRI)7. Another reason for the increase may be increased numbers of infected immigrant farm workers arriving from Latin America, where the problem is endemic7.

A case of human cysticercosis in the USA would involve visits to a physician, diagnosis by serology, confirmation by CT or MRI scan (and possibly a biopsy), treatment with praziquantel and sometimes corticosteroids and hospitalization. Surgery is sometimes necessary to relieve certain symptoms, and survivors often are unable to work. A rough calculation of the hospitalization costs and wage losses follows. One day at a community hospital averages US$817 (Ref. 18). A case of cysticercosis requires approximately eight days in hospital13, for a total of US$6536 per person per stay. This amount excludes the extra costs of CT or MRI scans and drug therapy. Assuming approximately 1100 cases of cysticercosis annually, the minimum total amount for hospitalization is US$7 million. Assuming it takes 19 days (off work) to recuperate, the wage losses per case would be US$1416, totaling US$1.6 million for all cases. Thus, a minimum estimate of the hospitalization and wage losses due to cysticercosis is US$8.8 million annually (Table 5). This total also excludes the value of the 66 lives lost (6% of 1100) and that of human suffering because of this illness.

Table 5.

Cysticercosis US annual costs 1992

Casesa (No.) Daysb (No.) Cost per day (US$) Cost per casec (US$) Costs (US$)
Hospitalized 1100 8 817 6539 7193368
Wages lostd 1100 19 73 1416 1557122
8750490
a

Preliminary data from Steahr’s analysis of NHDS data12.

b

It is arbitrarily assumed that there would be two days recuperation for each day of hospitalization.

c

Excluding cost of computer tomography and magnetic resonance imaging. Number of hospital days of income lost = [no. of hospital days + (2 × no. of hospital days) × 5/7].

d

Using the average private sector weekly wage (US$364.30) for 1991, Statistical Abstract of the US 1992 (Ref. 18).

Human cysticercosis is widely endemic in rural areas of Latin America, Asia and Africa19 (Table 6). Neurocysticercosis has been observed in 17 Latin American countries16,20. In Mexico, 1% of all deaths in general hospitals and 25% of intracranial tumors are estimated to be due to cysticercosis16. Velasco-Suarez estimated that 1% of the population of Mexico has neurological illness and that 6% of outpatients at the Neurological Institute in Mexico City had neurocysticercosis (42000 neurocysticercosis cases in 1982)21. The number of cases in 1992 (using the Velasco-Suarez methodology) is 52620. In Brazil in 1973, the incidence of cysticercosis was estimated at 1.5% from diagnoses at neurology and neurosurgery centers20. If 1% of the total population has neurological problems, as in Mexico, this implies almost 23000 cases of human cysticercosis in Brazil. Reported estimates in Latin America generally reflect data gathered in the major cities. In rural areas, rates can vary widely. A study in a Mexican village found 10.8% positive for cysticercosis by immunoassay in over 1500 blood samples22.

Table 6.

Cysticercosis: incidence in selected countries

Country Estimated % of population infected 1992 population (millions) Estimated cases (No.) Ref.
USA 0.0004 255.6 1100 13
Mexico 0.0600 87.7 52620 20
Brazil 0.0150 150.8 22620 20
Chile 0.0900 13.6 12240 21
Colombia 0.4500 34.3 154350 20
Costa Rica 0.5000 3.2 16000 20
Ecuador 0.4700 10.0 47000 33
El Salvador 0.4000 5.6 22400 20
Honduras 0.0200 5.5 1100 20
Venezuela 0.4900 18.9 92610 a
Cameroon 15.0000 12.7
1905000
24
598 2327040
a

R. Arroyo, Teniasis: Cisticercosis en Costa Rica Associacion Guatemalteca de Parasitology y Medicina Tropical, 1990.

Updating Velasco-Suarez21 estimates from 1982 to account for inflation and population increases, it is estimated that Mexican medical treatment costs in 1992 for neurocysticercosis were US$89 million and wage losses were US$107 million for an annual total of US$195 million. Applying the approximate cost per case in Mexico (about US$3700) to Brazil, total costs for 23000 cases would be approximately US$85 million.

Trichinellosis

Trichinellosis (infection by Trichinella spiralis) is caused by the ingestion of raw or undercooked pork contaminated with the organism. As physicians are required to notify the state or local health departments, who in turn notify CDC of trichinellosis cases, the CDC reports on the disease frequency. The latest CDC report for 1987–1990 indicated an annual average of 52 cases23. This average includes two large outbreaks that occurred in 1990. The number of cases have steadily decreased since the peak in the 1940s when the Public Health Service began collecting statistics. While three deaths were reported during 1982–1986, no deaths occurred from 1987 to 1990 (Ref. 7). However, this system sometimes results in underreporting. Approximately 131 cases were diagnosed and treated annually from 1987 to 1990 (T. Roberts and K.D. Murrell, abstract*). The authors assume the latter number (131 cases) more accurately portrays the extent of trichinellosis in the USA.

Assuming that all cases are hospitalized for an average of six days (T. Roberts and K.D. Murrell, abstract*) at US$817 per day for a total of US$4905 per case, hospitalization costs US$642499. Wage losses of six days in the hospital plus nine days to recuperate, at an average wage of US$73 per day, adds up to approximately US$1062 per case. The total wage loss is US$158000. Total costs (both hospitalization costs and wages lost) due to trichinellosis amount to US$781578.

Trichinellosis varies in importance as a human disease around the world. It has been cited as a continuing problem in China, Thailand, Germany, Yugoslavia, Poland and most of Eastern Europe24. The extent of the problem is unknown, since few incidence statistics are available. Poland has an estimated incidence of 0.015% (Ref. 25).

Liver fluke infections

Human infection with the liver fluke Opisthorchis viverrini (associated with consumption of undercooked fish) is an important problem in Laos and is the leading cause of foodborne parasitic disease in Thailand26. Sixty percent of the work force in Northeast Thailand are infected and their wage losses, estimated by Loaharanu and Sornmani26, and updated to 1992 prices, are US$76.5 million annually26. Hospitalization costs are US$10.6 million and drug costs US$12.8 million, for a total cost of US$99.9 million per year (Ref. 27).

Other parasitic infections

In the USA, 5108 annual cases of giardiasis, a water- or foodborne disease caused by Giardia lamblia, were diagnosed through a hospital discharge survey from 1987 to 1990 (Ref. 13). While most cases are water-borne, there have been documented cases of giardiasis that were foodborne. In a study of patients tested for giardiasis, five diagnostic tests cost US$338 per patient28.

In Japan, anisakiasis (caused by consumption of raw or undercooked fish) is the major foodborne disease. In the USA, it is less common, but anisakiasis is still the greatest threat to public health associated with US seafood29,30.

Summary

The fragmentary evidence of human disease caused by foodborne parasites indicates both an increasing ability to detect these public health problems and changing demographic, cultural and environmental practices that result in greater public health risk31. For example, both Thailand and the Philippines have a ‘plethora of foodborne parasitic zoonoses’ due to eating undercooked meat and seafood, poverty, illiteracy and poor hygiene and sanitation24. In China, improved living standards are resulting in an increase in the consumption of meat and seafood, with consequent rises in toxoplasmosis, clonorchiasis, cysticercosis and trichinellosis.

Foodborne disease is a worldwide problem of great magnitude, both in terms of the extent of human illness and the economic costs due to medical expenses and lost wages. Farm-level interventions are probably the most effective control strategy for parasites that originate on the farm, since they (unlike bacteria) do not multiply in food. In the USA, three management practices have been most effective in controlling T. spiralis in hogs: keeping rodents out of barns, restricting access to dead animals (including pigs), and cooking all feed that contains meat scraps or other animal by-products. We recognize that, in some countries, the climate and cost of housing may make it difficult to limit access of rodents to hogs, but the importance of this risk factor cannot be ignored. For fishborne parasites, control is inherently more difficult when cultural preferences for raw or undercooked fish are strong. However, the potential public health benefits that would result from more successful control of these particular zoonoses warrant greater research on practical means to reduce their incidence.

Footnotes

*

Symposium on Cost–Benefit Aspects of Food Irradiation (1993) IAEA/FAO/WHO, Aix-en-Provence, France

Contributor Information

Tanya Roberts, Economic Research Service, US Department of Agriculture, Washington, DC 20005-4788, USA.

K. Darwin Murrell, Beltsville Agricultural Research Center, Agricultural Research Service, USDA, Beltsville, MD 20705, USA.

Suzanne Marks, Economic Research Service, US Department of Agriculture, Washington, DC 20005-4788, USA.

References

  • 1.Roberts T, Frenkel JK. J Am Vet Med Assoc. 1990;196:249–256. [PubMed] [Google Scholar]
  • 2.Hsu H, et al. Scand J Infect Dis (Suppl) 1992;84:59–64. [PubMed] [Google Scholar]
  • 3.Henderson JB, et al. Int J Epidemiol. 1984;13:65–72. doi: 10.1093/ije/13.1.65. [DOI] [PubMed] [Google Scholar]
  • 4.Remington JS, Desmonts G, editors. Toxoplasmosis, Infectious Diseases of the Fetus and Newborn Infant. W.B. Saunders; 1989. [Google Scholar]
  • 5.Williams KAB, et al. J Infect. 1981;3:219–229. doi: 10.1016/s0163-4453(81)90773-8. [DOI] [PubMed] [Google Scholar]
  • 6.Berkow R, Fletcher AJ, editors. The Merck Manual of Diagnosis and Therapy. 16. Merck; 1992. [Google Scholar]
  • 7.Schantz PM, McAuley J. Southeast Asian J Trop Med Public Health. 1991;22:165–171. [PubMed] [Google Scholar]
  • 8.Dannemann BR, Remington JS. Hosp Med. 1989;24:139–144. doi: 10.1080/21548331.1989.11703682. [DOI] [PubMed] [Google Scholar]
  • 9.Dannemann BR, Remington JS. Hosp Med. 1989;24:151–154. doi: 10.1080/21548331.1989.11703682. [DOI] [PubMed] [Google Scholar]
  • 10.Hay JW, Osmond DH, Jacobson MA. J AIDS. 1988;7:466–485. [PubMed] [Google Scholar]
  • 11.McCabe R, Remington JS. New Engl J Med. 1988;318:313–315. doi: 10.1056/NEJM198802043180509. [DOI] [PubMed] [Google Scholar]
  • 12.Girdwood RWA. J Med Microbiol. 1989;30:3–16. doi: 10.1099/00222615-30-1-3. [DOI] [PubMed] [Google Scholar]
  • 13.Steahr TE, Roberts T. NE-165 Working Paper No. 32. Food Marketing Policy Center University of Connecticut; Storrs: 1993. Microbial Foodborne Disease: Hospitalization, Medical Costings and Potential Demand for Safer Food. [Google Scholar]
  • 14.Luft BJ, Remington JS. J Infect Dis. 1988;157:1–6. doi: 10.1093/infdis/157.1.1. [DOI] [PubMed] [Google Scholar]
  • 15.Soulsby EJL. PAHO/WHO Sci Publ. 1975;295:122–126. [Google Scholar]
  • 16.Sorvillo FJ, et al. Am J Trop Med Hyg. 1992;47:365–371. doi: 10.4269/ajtmh.1992.47.365. [DOI] [PubMed] [Google Scholar]
  • 17.Medina MT, et al. Arch Int Med. 1992;150:325–327. [PubMed] [Google Scholar]
  • 18.Anonymous. Statistical Abstract of the United States. 112. Bureau of the Census, US Department of Commerce, US Government Printing Office; 1992. [Google Scholar]
  • 19.Anonymous. Morbidity and Mortality Weekly Report. Centers for Disease Control; 1992. [Google Scholar]
  • 20.Schenone H. PAHO/WHO Sci Publ. 1975;295:122–126. [Google Scholar]
  • 21.Velasco-Suarez M, Bravo-Bechelle MA, Quirasco F. In: Cysticercosis: Present State of Knowledge and Perspectives. Flisser A, editor. Academic Press; 1982. pp. 21–43. [Google Scholar]
  • 22.Sarti E, et al. Am J Trop Med Hyg. 1992;46:677–685. doi: 10.4269/ajtmh.1992.46.677. [DOI] [PubMed] [Google Scholar]
  • 23.McAuley JB, Michelson MK, Schantz PM. Morbidity and Mortality Weekly Report. Centers for Disease Control; 1991. [PubMed] [Google Scholar]
  • 24.Cross JH, Murrell KD. Southeast Asian J Trop Med Public Health. 1991;22:4–15. [PubMed] [Google Scholar]
  • 25.Steele JH. CRC Handbook Series in Zoonosis. 2C. CRC Press; 1983. [Google Scholar]
  • 26.Loaharanu P, Sornmani S. Southeast Asian J Trop Med Public Health. 1991;22:384–390. [PubMed] [Google Scholar]
  • 27.Haswell-Elkins MR, Sithithaworn P, Elkins D. Parasitology Today. 1992;8:86–89. doi: 10.1016/0169-4758(92)90241-s. [DOI] [PubMed] [Google Scholar]
  • 28.Chappell CL, Matson CC. J Fam Pract. 1992;35:12–19. [PubMed] [Google Scholar]
  • 29.Ahmed FE. Seafood Safety: Committee on Evaluation of the Safety of Fishery Products, Food and Nutrition Board, Institute of Medicine. National Academy Press; 1991. [DOI] [PubMed] [Google Scholar]
  • 30.Higashi GI. Food Technol. 1985;39:19–74. [Google Scholar]
  • 31.Murrell KD, Fayer R, Dubey JP. In: Advances in Meat Research. Pearson AM, Dutson TR, editors. Vol. 2. AVI Publishing; 1986. pp. 311–377. [Google Scholar]
  • 32.Bjerkedal T, Erickson JD. Am J Obstet Gynecol. 1983;147:399–404. doi: 10.1016/s0002-9378(16)32233-5. [DOI] [PubMed] [Google Scholar]
  • 33.Gomez AD. Programa de Control de Taeniasis, Cysticercosis, Ministerio de Salud, Direccion de Saneemient. Ambiental, Division de Alimentos; Zoonosis, Bagota, Columbia: 1990. [Google Scholar]

RESOURCES